Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 8/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069803 | 0.98 | BCHE (0.54) | BCHEMAPTKDM4ENPC1RAB9A | |
| SCHEMBL2070396 | 0.87 | MAPT (0.65) | MAPTKDM4ENPC1RAB9ATP53 | |
| SCHEMBL2069324 | 0.86 | SMN1; SMN2 (0.56) | MAPTKDM4ENPC1RAB9ATP53 | |
| SCHEMBL7502551 | 0.85 | KDM4E (0.68) | MAPTKDM4ENPC1RAB9ATP53 | |
| SCHEMBL330358 | 0.85 | MAPT (0.63) | BCHEMAPTKDM4ENPC1RAB9A | |
| SCHEMBL329814 | 0.85 | XDH (0.55) | MAPTKDM4ENPC1RAB9ATP53 | |
| SCHEMBL12055335 | 0.84 | MAPT (0.60) | BCHEMAPTKDM4ENPC1RAB9A | |
| SCHEMBL2069573 | 0.84 | MAPT (0.57) | MAPTKDM4ENPC1RAB9ATP53 | |
| SCHEMBL4300808 | 0.83 | MAPT (0.61) | MAPTKDM4ENPC1RAB9ATP53 | |
| SCHEMBL7509276 | 0.82 | MAPT (0.58) | MAPTKDM4ENPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-10-06 | — | — | US | disclosed |
| US-9381186-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-12-10 | — | — | US | disclosed |
| US-9138478-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2407462-B1 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS INC (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2407462-B1 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8697891-B2 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2407462-A1 | Substituted chroman derivatives, medicaments and use in therapy | Marshall Edwards, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| EP-1794141-A4 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RES PTY LTD (AU) | 2009-05-27 | — | — | EP | disclosed |
| US-20080306140-A1 | Isoflavonoid Dimers | NOVOGEN RESEARCH PTY LTD (AU) | 2008-12-11 | — | — | US | disclosed |
| US-20080306140-A1 | Isoflavonoid Dimers | NOVOGEN RESEARCH PTY LTD (AU) | 2008-12-11 | — | — | US | disclosed |
| US-20080306140-A1 | Isoflavonoid Dimers | NOVOGEN RESEARCH PTY LTD (AU) | 2008-12-11 | — | — | US | disclosed |
| EP-1861402-A1 | ISOFLAVONOID DIMERS | Novogen Research Pty. Ltd. (AU) | 2007-12-05 | — | — | EP | disclosed |
| EP-1794141-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | Novogen Research Pty. Ltd. (AU) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006099681-A1 | ISOFLAVONOID DIMERS | NOVOGEN RESEARCH PTY LTD (AU) | 2006-09-28 | — | — | WO | disclosed |
| US-20060074127-A1 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD | 2006-04-06 | — | — | US | disclosed |
| WO-2006032085-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | BCHE 2563/4885MAPT 3391/4885KDM4E 1878/4885 |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | BCHE 2563/4885MAPT 3391/4885KDM4E 1878/4885 |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | BCHE 2563/4885MAPT 3391/4885KDM4E 1878/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | BCHE 1640/4885MAPT 3422/4885KDM4E 3617/4885 |
| US-20060074127-A1 | anticancer agents; chemotherapeutic selective agents | MCL1, TOP2A, TP53 | BCHE 2833/4885MAPT 3789/4885KDM4E 2793/4885 |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | BCHE 2563/4885MAPT 3391/4885KDM4E 1878/4885 |
| US-20080306140-A1 | Isoflavonoid Dimers | CDK2, CDK20, F2 | BCHE 4536/4885MAPT 2378/4885KDM4E 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.